Eli Lilly has stated it "remains confident in the differentiated benefits of tirzepatide." Facing generic competition, Novo Nordisk has taken several steps: Launch of rebranded versions In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: These are identical to the branded versions but come in different packaging
By correcting these imbalances, you unlock the full potential of your medication
While Mounjaros primary focus is diabetes treatment, its potential for weight management is promising
Patients frequently mention: Staff who are polite, patient, and knowledgeable Representatives who take the time to walk through instructions Managers who follow up personally when a question needs extra attention Team members who make the process easy and stress-free Several reviews specifically mention staff members being thorough, friendly, and detail-oriented, which patients appreciate when dealing with compounded medications
While the mechanism behind this is not fully clear, it seems the effects of semaglutide on digestive processes and hormones may reduce saliva production in some people
On average, studies show most people living with obesity lose between 15% and 25% of their body weight after just one year on a GLP-1